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Abstract
Systematic analysis of synthetic lethality (SL) constitutes a critical tool for systems biology to decipher molecular pathways.
The most accepted mechanistic explanation of SL is that the two genes function in parallel, mutually compensatory
pathways, known as between-pathway SL. However, recent genome-wide analyses in yeast identified a significant number
of within-pathway negative genetic interactions. The molecular mechanisms leading to within-pathway SL are not fully
understood. Here, we propose a novel mechanism leading to within-pathway SL involving two genes functioning in a single
non-essential pathway. This type of SL termed within-reversible-pathway SL involves reversible pathway steps, catalyzed by
different enzymes in the forward and backward directions, and kinetic trapping of a potentially toxic intermediate.
Experimental data with recombinational DNA repair genes validate the concept. Mathematical modeling recapitulates the
possibility of kinetic trapping and revealed the potential contributions of synthetic, dosage-lethal interactions in such a
genetic system as well as the possibility of within-pathway positive masking interactions. Analysis of yeast gene interaction
and pathway data suggests broad applicability of this novel concept. These observations extend the canonical
interpretation of synthetic-lethal or synthetic-sick interactions with direct implications to reconstruct molecular pathways
and improve therapeutic approaches to diseases such as cancer.
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Introduction
Synthetic interactions between two mutations in different genes
were first revealed in Drosophila by Dobzhansky in the 1940s [1].
Synthetic lethality (SL) describes that two viable single gene
mutations lead to lethality (synthetic-lethal) or severely impair
growth (synthetic-sick) when combined as a double mutant. This
concept was implemented as a powerful research tool for
molecular pathway analysis in yeast [2–5]. Further refinement
introduced more quantitative measures of genetic epistasis [6] and
lethality induced by gene overexpression in a mutant background
(synthetic dosage-lethality [7]). A genetic interaction is negative or
aggravating, when the combined effect of two gene defects is more
severe than it is expected from a simple multiplicative model. In a
positive or alleviating interaction the effect is less severe than
expected. These approaches and measures are now increasingly
used in mammalian cells exploiting RNA-mediated gene knock-
down technologies [8,9].
Following a proposal by Hartwell and colleagues [10], SL has
been utilized as a therapeutic approach in cancer treatment
employing a combination of genetic ablation (loss of tumor
suppressor) and chemical inhibition. The first paradigm was set in
BRCA1/2-deficient tumor cells, which are synthetic-lethal with
inhibition of PolyADP-Ribose Polymerase (PARP) [11–13]. Small
molecule PARP inhibitors are currently being evaluated in clinical
trials in BRCA1- and BRCA2-deficient cancers (e.g. [14]).
The canonical interpretation of SL stipulates two mutually
compensatory, parallel pathways capable of performing the same
essential function [2–4]. Thus, disrupting a single pathway is
viable, while disrupting both pathways is lethal. This concept of
between-pathway synthetic lethality (bpSL) (Figure 1A) led to the
creation of computational approaches aiming at reconstructing
interaction networks from pair-wise gene deletions or siRNA-
induced gene knock-down screens in yeast and mammals [15–17].
However, recent genome-wide genetic interaction data revealed
multiple negative interactions between mutations affecting the
same molecular pathway or complex [3,5,16,18–21]. For example,
it was estimated that ,9% [19] and in another study 14% [17] of
all negative genetic interaction clusters belong to the same
biological pathway. Several mechanistic models were suggested
to explain within-pathway SL (wpSL) [6,16,20,22]. The deletion of
a gene might lead only to a partial degradation of an essential
pathway which might be tolerable, whereas the double mutation
leads to complete pathway degradation and lethality (Figure 1B1).
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This is especially relevant for the interpretation of siRNA-based
screens where the efficiency of a particular gene knock down is
uncertain. A second possible mechanism suggests that steps in an
essential pathway are internally redundant (Figure 1B2). Lastly,
two mutations may cumulatively degrade an essential protein
complex, whereas they are individually viable (Figure 1B3). This
mechanism is consistent with the observations that molecular
complexes are frequently characterized by the dominance of
negative over positive genetic interactions between their compo-
nents [18]. wpSL interactions between defects in components of a
single protein complex are highly enriched for complexes with an
essential component [16,22]. It was estimated that the contribu-
tion from within-complex interactions to the total number of
within-pathway negative interactions does not exceed 7% [19].
Common to these mechanistic explanations of wpSL is that they
involve either an essential pathway or an essential protein
complex.
Here, we highlight a novel scenario of wpSL involving two
components of a non-essential pathway. The view of molecular
pathways as unidirectional, linear reaction cascades is too
simplistic. Pathway steps can be reversible which leads to forward
and backward propagation of molecular events along the pathway
increasing robustness and fidelity of the overall process [23–28].
Affecting both forward and reverse steps of the pathway by
abrogating the corresponding enzymes creates scenarios in which
the pathway flow can be trapped in an intermediate state that may
be toxic to the cell or deprive the cell of a limiting resource
(Figure 1C). This can create a genetic scenario we define as within-
reversible-pathway synthetic lethality (wrpSL), which is the subject
of this study.
Here, we study bpSL and wrpSL scenarios using mathematical
modeling to better understand the system properties of these
genetic relationships. We present a simplified model of the
pathway applicable for its formal analytical study and performed
in silico simulations for bpSL and wrpSL as well as synthetic dosage
effects. Our main experimentally confirmed examples of wrpSL
are in the homologous recombination DNA repair pathway.
Figure 1. Schematic representation of mechanisms of (A)
between-pathways Synthetic Lethality, (B) within-pathway
Synthetic Lethality, and (C) within-reversible-pathway Syn-
thetic Lethality. S: substrate, I: intermediate, P: product, C1–4:
components of a protein complex. Red crosses define single mutations.
For details see text.
doi:10.1371/journal.pcbi.1003016.g001
Author Summary
Organizing gene functions into molecular pathways is a
major challenge in biology. The observation that two
viable gene mutations become lethal when combined as a
double mutant has been developed into a major genetic
tool called synthetic lethality. The classic interpretation of
synthetic lethality stipulates that the two mutations
identify genes that work in parallel, mutually compensa-
tory pathways that together perform an essential function.
However, a significant number of negative interactions are
caused by defects affecting a single molecular pathway.
Here, we recapitulate by mathematical modeling recent
experimental data that demonstrate synthetic lethality
between mutations in genes acting in a single, non-
essential molecular pathway. We propose a novel mech-
anism involving reversible pathways steps and trapping of
an intermediate. The modeling also predicts that overex-
pression of certain genes functioning in reversible path-
ways will lead to synthetic lethality with gene defects in
the same pathway. Our results significantly broaden the
interpretation of synthetic lethal and synthetic dosage
effects, which fundamentally impacts the assignment of
genes to pathways. The concept of synthetic lethality has
been applied to cancer therapy, and our modeling results
suggest new approaches to how to target a single pathway
to induce synthetic lethality in cancer cells.
Within-reversible-pathway Synthetic Lethality
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Homologous recombination (HR) is an important mechanism to
maintain genome integrity [29] (Section S1 and Figure S1 in Text
S1 for more discussion). Analysis of yeast gene interaction and
pathway data suggests broad applicability of this novel concept.
Results
Homologous recombination and other DNA repair
pathways are a hotspot for negative genetic interactions
In order to assess the importance of within-pathway negative
interactions we ranked all pathways from the KEGG database
[30] according to their normalized proportion of negative
interactions [5] within each KEGG pathway (Figure 2). This
analysis confirms the previous conclusion [19] that only a minority
of within-pathway negative interactions can be explained by
negative interactions within a complex (Figure 1B3). In our
analysis only 12% of all negative interactions were of this type
(compared to 7% in [19]). Interestingly, HR ranks at the top with
27 within-pathway negative interactions between 20 KEGG
pathway components (Figure 2), of which only a single one affects
components of the same protein complex.
Reversibility of the pathway steps in homologous
recombination pathway
Recent studies show that individual reaction steps in HR are
reversible [23–25] (Figure S1 in Text S1). The Rad51-ssDNA
filament is a key intermediate in HR, as it performs the signature
reactions of homology search and DNA strand invasion. The
Figure 2. Normalized proportion of negative genetic interactions within one KEGG pathway. The proportion is related to the number of
all possible pairwise interactions S(S21)/2, where S is the size of the KEGG pathway. Negative interactions between components of a molecular
complex were excluded (compare the fourth and the fifth columns). We counted the normalized number of negative genetic interactions within one
pathway using recent data on the genome-wide screening of genetic interactions in yeast from [5], using the most stringent filter on the epistasis
measure e. Definitions of yeast signaling and metabolic pathways were taken from KEGG database [30]. Only KEGG pathways with a normalized
proportion of $1% are shown. DNA repair KEGG pathways are highlighted in bold.
doi:10.1371/journal.pcbi.1003016.g002
Within-reversible-pathway Synthetic Lethality
PLOS Computational Biology | www.ploscompbiol.org 3 April 2013 | Volume 9 | Issue 4 | e1003016
formation of this filament is catalyzed by specific co-factors (see
Section S1 and Figure S1 in Text S1). The helicase Srs2
specifically targets the Rad51-ssDNA filament for disruption to
reverse filament formation [31,32,33]. The reversibility of the
Rad51-ssDNA filament sets a new paradigm and draws attention
to additional reversible steps and their mechanisms in HR, other
DNA repair processes, and unrelated molecular pathways.
Simplest abstract toy model of DNA repair pathway with
reversible steps and a toxic intermediate
We derived the simplest linear mathematical model of a main
DNA repair pathway with reversible steps and a toxic interme-
diate, and a compensatory pathway, which can recapitulate bpSL
and wrpSL (Figure 3). Each state transition is catalyzed by an
abstract enzyme, which may correspond to several biological
entities (compare Figure S1 in Text S1 with Figure 3). In wrpSL
trapping of toxic intermediate I is caused by defects in the first
backward reaction (IRS, R1, k21) and the second forward
reaction (IRP, F2, k2). The reversibility of the second step
(reaction PRI, R1) is not essential for wrpSL to occur, but might
be important for quantitative pathway characteristics. Introduc-
tion of a final irreversible step (Figure S2 in Text S1) would result
in a kinetic proofreading mechanism [34] (see Figures S2, S3 in
Text S1 and discussion there). Such a mechanism increases the
robustness of DNA repair, as it avoids a futile P«I cycle.
However, in this simplest model we eliminated the final
irreversible step to allow us analyzing the most essential features
of wrpSL (Section S2 in Text S1). Figure 4 explores conditions for
various cellular fates (Normal Robust, NR: no single knockout
leads to lethality (Figure S4 in Text S1); Normal Fragile, NF: single
knockout can lead to lethality (Figure S4 in Text S1); Compen-
sated, C: repair is performed by compensatory pathway; death due
to DNA Damage, DD: steady state probability of DNA damage
.50%; and Death due to Toxic intermediates, DT: steady state
probability of toxic intermediate .50%). Figure 5 visualizes
parametric conditions (see Section S2B in Text S1 for discussion).
Examples of numerical simulations of the toy model
Using analytical study and numerical simulations with some
characteristic choices of kinetic rate values, we explored the dynamical
behaviors of the simplest model (see Figure 6). Here, we discuss the
qualitative results and interpretations, while the more formal
derivation of these statements is found in Section S3 in Text S1. To
illustrate the static and dynamic properties of the toy model, we
selected two typical positions (Figure 5#1,#2) corresponding to NR
and NF pathway states, respectively. From these ‘‘normal’’ conditions
we simulated a number of single and double mutant/overexpression
conditions as shown in Figure 5 (see also Figure S4 in Text S1).
Normal pathway vs. irreversible pathway: reversibility
does not affect efficiency, but is essential for pathway
robustness. We assume that in the NR and NF states under
normal conditions forward steps of the pathways are faster than
the backward steps. In this case the presence of reversible steps
does not significantly affect the numerical solutions of the model
equations, i.e. the efficiency of DNA repair (Figure 5 cases 1–3;
Figure 6, rows 1–3; Figure S4 in Text S1). However, the presence
of reversible steps is important from the robustness point of view
(Figure 5 cases 3, 7; Figure 6, rows 3, 7; Figure S4 in Text S1). The
gain in robustness through backward reactions is also illustrated by
the fact that the difference between the NR and NF states is
entirely defined by the ratio of the two backward reactions (rb). The
model recapitulates the fact that single enzyme deficiencies are not
capable to completely block the overall DNA repair network. The
F2 knock-out in NF is the only exception. When the first backward
reaction is relatively slow k{1%
k{2|k1
k3
, the compensatory
pathway cannot rescue the lethal phenotype (Figure 5 case 8;
Figure 7, row 8; Figure S4 in Text S1). This underlines the
importance of efficient backward reactions.
Between-pathway Synthetic Lethality (bpSL): Disruption
of main and compensatory pathways. The model recapitu-
lates canonical bpSL by putting two kinetic rates to zero
simultaneously: k1 = k3 = 0 which causes cell death from accumu-
lation of DNA damage (DD) (Figure 5 case 4; Figure 6, row 4;
Figure S4 in Text S1). Alternatively, in the case of k2 = k3 = 0 the
pathway state will be DT, resulting in cell death from accumu-
lation of toxic intermediates.
Within-reversible-pathway Synthetic Lethality (wrpSL):
Trapping a toxic intermediate. The wrpSL case is modeled
by putting k2~k{1~0. As it can be seen (Figure 5 case 5;
Figure 6, row 5; Figure S4 in Text S1), this creates a kinetic trap in
the toxic intermediate state I (DT). The model recapitulates the
situation observed in the srs2 rad54 double mutant [23,35,36].
Modeling predicts that mammalian cells deficient in RAD54 or its
close paralog RAD54B should also be sensitive to inhibition of
enzymes, such as FBH1, FANCJ, or RECQ5 [37–39] (Figure 5
cases 5, 8; Figure 6, row 5; Figure 7, row 8; Figure S4 in Text S1),
that are postulated or shown to dissociate the RAD51-ssDNA
filament (Figures S1, S2 in Text S1).
Aspects of reversibility. Blocking the pathway upstream by
eliminating the F1 reaction in the normal pathway states (NR and
NF) does not lead to cell death. However, this affects the kinetics of
the process, because repair is carried out by the compensatory
pathway (state C), which is slower than the principal one (Figure 5
case 6; Figure 6, row 6; Figure S4 in Text S1). Therefore, the time
of repair increases and the cell fate depends on the efficiency of the
Figure 3. Abstract representation of the recombinational DNA
repair pathway. The scheme represents a simplified version of the
pathway depicted in Figure S1 in Text S1 using the same abbreviations.
Dynamic states S, I, P represent DNA damage substrate (S), toxic
intermediate (I), and the product of repair (P). F1 (e.g. Rad51), F2 (e.g.
Rad54), R1 (e.g. Srs2), R2 (e.g. Mph1) are enzymes in the main pathway,
and F3-EC represent enzymes in the compensatory pathway. ks signify
the kinetic rates of the model state transition steps. The two types of
synthetic lethality (SL) are indicated: Red Xs – classic scenario of
between-pathway SL (e.g. BRCA1 or BRCA2 mutant and PARP inhibition);
Green Xs – within-reversible-pathway SL between two mutations in
genes acting in a single non-essential pathway leading to the
accumulation of a toxic intermediate (e.g. srs2 rad54 double mutant).
For more discussion see also Section S1 in Text S1.
doi:10.1371/journal.pcbi.1003016.g003
Within-reversible-pathway Synthetic Lethality
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compensatory pathway, which might be cell type-specific. The
situation may result in cell death if the kinetics of the process are
too slow or the efficiency of DNA damage repair by the
compensatory pathway is below an essential threshold. This
scenario may represent cancer cells with certain DNA repair
defects, which can be compensated by alternative pathways. In
such cases, therapeutic targeting of the compensatory pathways
may result in fast accumulation of DNA damage, selectively killing
the cancer cells, representing the classic bpSL concept.
When the pathway is blocked downstream at F2 (Figure 5 case
7; Figure 6, row 7; Figure S4 in Text S1) the time of repair
significantly increases, as the pathway is only partially compen-
sated. This scenario can be rescued by reducing k1 or increasing
k21 (state C). The scenario recapitulates RAD54-deficient cells,
where sub-lethal levels of toxic intermediates and unrepaired DNA
increase genetic instability [36,40]. This last scenario of a
downstream block (F2 knockout: Figure 5 case 7; Figure 6, row
7; Figure S4 in Text S1) can be rescued by overexpression of R1
Figure 4. Pathway steady states for various combinations of parameters in the mathematical model of DNA repair with reversible
steps and a toxic intermediate. The classification of pathway steady states depends on the values of three control parameters, representing the
ratios of some kinetic rates of the model (for more details see Section S2A in Text S1):
r2:
k2
k{2
, r3|rb:
k3
k1
|
k{1
k{2
and r1:
k1
k{1
:
The diagrams visualize the values of the control parameters where thickness of the solid arrows shows the relative value of the corresponding kinetic
rate and the dashed arrows represent kinetic rates which values are irrelevant for a given scenario. Color coding shows partial orderings of the
parameters important for a given pathway state (thickness of edges of the same color should be compared but not between color.
doi:10.1371/journal.pcbi.1003016.g004
Within-reversible-pathway Synthetic Lethality
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(Figure 5 case 9; Figure 7, row 9; Figure S4 in Text S1). The
modeling predicts that this will accelerate the backward reactions,
favor the compensatory route and increase repair of damaged
DNA by the compensatory pathway (state C). The modeling also
highlights the benefit of reversibility. In Figure 7 (row 8), a
decrease in reversibility (10-fold reduction in R1) leads to
significantly less repaired product in mutants that block the
downstream step (F2). Complete inhibition of the R1 step leads to
wrpSL in cells lacking F2, such as RAD54B-deficient cells (Figure 5
case 8; Figure 7, row 8; Figure S4 in Text S1, see above). The
modeling suggests that cells deficient in the downstream forward
reaction (F2, e.g. RAD54B2/2) are potentially under selective
pressure to strengthen the upstream backward reaction (R1, e.g.
overexpression of FBH1, FANCJ, or RECQ5).
Activating mutations or overexpression can create within-
reversible-pathway-synthetic dosage lethality. The compu-
tational model allows making predictions in less intuitive cases of
model perturbations. The lethal phenotype by R2 overexpression
(Figure 5 case 10; Figure 7, row 10; Figure S4 in Text S1) can be
partially rescued by eliminating F1 (Figure 5 case 12; Figure 7, row
12; Figure S4 in Text S1), as repair is carried out by the
compensatory pathway (state C). The modeling illustrates how a
defect in an early HR gene such as RAD51, BRCA2, RAD52, or the
RAD51 paralogs would provide a selective advantage in cells
overexpressing enzymes of the R2 backward reaction (yeast Mph1,
human RTEL1 or FANCM).
F1 overexpression amplifies the effect of an F2 mutation,
creating synthetic-lethal dosage and leading to wrpSL due to the
accumulation of toxic intermediates (state DT) (Figure 5 case 13;
Figure 7, row 13; Figure S4 in Text S1). This suggests that
inhibition of F2 (for example RAD54/RAD54B) would be
particularly effective to sensitize cancer cells overexpressing F1
components (e.g. RAD51 paralogs, RAD51, RAD52, BRAC2 [41–
45]), a non-intuitive insight derived from the mathematical
modeling.
Blocking the compensatory pathway and overexpressing R2 also
creates synthetic lethal dosage interaction, causing accumulation
of toxic intermediates due to the increase in backward reactions
kinetics (state DT) (Figure 5 case 14; Figure 7, row 14; Figure S4 in
Text S1). However, if the final irreversible step of DNA repair will
Figure 5. Visualization of the steady states for the toy model in dependence of various parameters. The phase diagrams (r26r1 plane)
show the qualitative behavior for small, intermediate and large values of the model parameters. Red color corresponds to the state for which Ps.0.5
(DNA is repaired with probability.50%). If Ps,0.5 then the color is chosen as green if the probability of trapping in the intermediate state (I) is bigger
than the propability of the initial unrepaired state (S), and as blue in the opposite case. The case k1 = 0 (F1Q) is represented separately on the right. In
this case, another parameter rs:
k3
k{1
is used instead of r1 for the phase plane. The case k21 = 0 (R1Q) is treated separately on the top and only the r2
value is varied. The 14 model simulations listed in Figure 6 are shown by the circled numbers in the position of the chosen parameters.
doi:10.1371/journal.pcbi.1003016.g005
Within-reversible-pathway Synthetic Lethality
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Figure 6. Modeling possible scenarios of single and double synthetic lethal mutations. Pathway steady states depicted as Normal states
(N) as Normal Robust (NR) and Normal Fragile (NF); Mutant states (M) as compensated state dependent on compensatory pathway EC(C); death
from DNA damage (DD) and death from toxicity (DT). Dynamic plots show prediction of model for evolution of substrate (S), intermediate (I) and
product (P) amounts over time corresponding to the choice of kinetic parameters shown on the Model diagram. (X-axis)-time, (Y-axis)-
substances level. F1, F2, R1, R2, and EC refer to the enzymes catalyzing the two forward and two backward reactions as well as the compensatory
pathway, respectively (see Figure 3). (Q)-complete knock-down or mutational loss of function; (q)-over-expression. A deletion mutant was simulated
by setting the corresponding kinetic rate constant to zero. An overexpression mutant was simulated by setting the corresponding kinetic rate
constant sufficiently high to have a qualitative effect onto the steady state or the dynamics in the simulations. Some double mutants are not shown
due to their triviality (such as F1QF2Q) or difficulties with interpretation (such as F1QR1Q). For more modeling scenarios see Figure S5 in Text S1.
doi:10.1371/journal.pcbi.1003016.g006
Within-reversible-pathway Synthetic Lethality
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be taken into consideration (PRI2a/bREP, Figure 3), slow
conversion of all favorable DNA configurations from the futile
I«P cycle into the completely repaired DNA state will rescue cells
(similar to scenario depicted in Figure 7, row 10). This example is
interesting, because it demonstrates that interference with
compensatory pathways by drugs might have a therapeutic
importance if the backward steps of the main pathway are
considered. Finally, the computational model predicts that a
Figure 7. Modeling possible scenarios of single and double synthetic lethal mutations (continued). Pathway steady states depicted as
Normal states (N) as Normal Robust (NR) and Normal Fragile (NF); Mutant states (M) as compensated state dependent on compensatory
pathway EC(C); death from DNA damage (DD) and death from toxicity (DT). Dynamic plots show prediction of model for evolution of substrate (S),
intermediate (I) and product (P) amounts over time corresponding to the choice of kinetic parameters shown on theModel diagram. (X-axis)-time,
(Y-axis)-substances level. F1, F2, R1, R2, and EC refer to the enzymes catalyzing the two forward and two backward reactions as well as the
compensatory pathway, respectively (see Figure 3). (Q)-complete knock-down or mutational loss of function; (q)-over-expression. A deletion mutant
was simulated by setting the corresponding kinetic rate constant to zero. An overexpression mutant was simulated by setting the corresponding
kinetic rate constant sufficiently high to have a qualitative effect onto the steady state or the dynamics in the simulations. Some double mutants are
not shown due to their triviality (such as F1QF2Q) or difficulties with interpretation (such as F1QR1Q). For more modeling scenarios see Figure S5
in Text S1.
doi:10.1371/journal.pcbi.1003016.g007
Within-reversible-pathway Synthetic Lethality
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similar trap in the intermediate state can be created by eliminating
R1 and overexpressing R2 (Figure 5 case 3; Figure S4 in Text S1;
Figure S5, row 3 in Text S1).
Discussion
Synthetic lethality/sickness and synthetic dosage lethality are
important genetic tools to assign individual gene functions into
molecular pathways [2–4,7–9]. The canonical interpretation for
two mutants found to be synthetically lethal or sick stipulates that
the encoded gene products function in different parallel pathways
that can mutually compensate (bpSL) [2–4,7–9,15–17]. However,
computational analysis of genetic interaction data combined with
protein interaction data revealed multiple negative interactions
between mutations affecting functions in the same molecular
pathway or complex (wpSL) [3,5,16,18–21]. Several mechanisms
of wpSL have been proposed (Figure 1B), and they all involve
either essential pathways or essential protein complexes. In
extension of this fundamental concept of wpSL, there are several
cases of SL between mutants encoding proteins acting in HR, a
pathway that is not essential in yeast [35,46–48]. We term this
novel genetic interaction within-reversible-pathway Synthetic
Lethality (wrpSL; Figure 1C) and provide a novel mechanistic
explanation for wpSL, which can create SL within a non-essential
pathway or between hypomorphic mutations in an essential
pathway that is different from a model invoking sequential
pathway degradation by accumulation of partial defects of
successive steps (Figure 1B1).
Here, we explore by mathematical modeling the system
properties of wrpSL. The modeling must make assumptions about
the system properties (state transition rates, relative pathway
efficiencies, etc.) and identifies several conditions to be met for
wrpSL. 1) Reversibility of pathway steps. In fact, only the first
pathway step must be reversible, whereas reversibility of the
second pathway steps enables additional genetic scenarios. 2)
Possibility of kinetic trapping of an intermediate state of the
pathway when both the backward and forward reactions are
compromised. The trapping per se can be detrimental due to
blockage of cell signaling, sequestering an essential compound, or
toxicity. We have assumed lethal toxicity in our model. 3) The
possibility of rescue by a parallel compensatory pathway may not
be strictly required, but highlights the applicability of this concept
to non-essential pathways.
The mathematical model is validated by the experimentally
observed recombination-dependent SL of the srs2 rad54 double
mutant in budding yeast [35] (Figure 3, Figure S1 in Text S1,
Figure 6, row 5). Srs2-defective cells are unable to reverse Rad51-
ssDNA filaments. These Rad51-ssDNA filaments represent toxic
intermediates that accumulate in the cell due to kinetic trapping and
interfere with cell viability. The key functions of the Rad54 protein
are to assist in DNA strand invasion and allowing DNA synthesis off
the invading 39-end [36]. Hence, in the srs2 rad54 double mutant
Rad51-ssDNA filaments and/or D-loops may accumulate forming
a toxic intermediate that leads to cell death (Figure S1 in Text S1;
Figure 3 green pair and Figure 6, row 5). This interpretation is
supported by the observation that lethality in this double mutant is
suppressed by a defect in Rad51-ssDNA filament formation
(mutations in RAD51, RAD55, RAD57, or RAD52) [49] (see Figure
S1 in Text S1), what has been termed recombination-dependent
lethality. Preventing Rad51-ssDNA filament formation allows
bypass of recombination by alternative means of DNA repair (for
DSBs: Nonhomologous endjoining or single-strand annealing; for
gaps: Translesion synthesis or fork regression [23]; see Figure S1 in
Text S1). The recombination-dependent lethality of srs2 rad54 is not
unique and is also found in additional double mutants in
recombinational repair genes including the double mutants mph1
mus81, mph1 mms4, srs2 sgs1 and sgs1 (or top3 or rmi1) and mus81 (or
mms4) which likely reflect additional examples of wrpSL possibly
involving different toxic intermediates [35,46–53]. As discussed in
detail in Section S1 in Text S1, the synthetic lethalities involving sgs1
are more complex, because of the multiple roles of Sgs1-Top3-Rmi1
in HR, and could be caused also by other mechanisms of SL.
Further modeling revealed additional genetic conditions
including overexpression of specific pathway enzymes that are
predicted to lead to wrpSL (Figure 6). The mathematical modeling
also reveals the importance of reversible pathway steps, which are
validated by genetic and biochemical experiments in yeast [23–
25]. First, the existence of reversible pathway steps does not affect
normal pathway progression (Figure 6, rows 1–3). Second,
reversible pathway steps allow much more efficient and timely
use of compensatory pathways (Figure 6, row 6). Third, reversible
pathways coupled with compensatory pathways avoid lethality of
single mutations (Figure 6, row 7). The existence of reversible
intermediates in HR, and possibly other molecular pathways, has
been proposed to increase the robustness of the overall DNA
repair system [23–25], and here we provide quantitative modeling
evidence and formal analysis of this assertion.
An important question is how general wrpSL might be or
whether it is an idiosyncrasy of the recombinational repair
pathway. Even if wrpSL were restricted to HR, this concept
provides significant potential application in anti-cancer therapy.
However, there is considerable evidence that many molecular
pathways include reversible steps catalyzed by different enzymes in
the forward and backward directions (see Figure 8). Any of those
processes can be theoretically trapped into one of their interme-
diate states if two regulators of forward and backward steps are
inactive. In these cases, the accumulating intermediate might be
toxic, block proper signal propagation or prevent resource
recycling. Focusing on three examples of reversible protein
modifications (phosphorylation by Cdc5/dephosphorylation by
Cdc14, sumoylation by Slx5–Slx8/desumoylation by Ulp1,
Nup60, ubiquitylation by Rad6–Rad18/deubiquitylation by
Bre5, Ubp3 or degradation dependent on Doa1, Rpn6; see Figure
S6 in Text S1 for details), we found ample evidence in published
genetic interaction data that are consistent with the wrpSL
mechanism. These examples have not been fully explored, but are
consistent with the wrpSL concept and amenable to test specific
predictions.
In summary, genetic and biochemical data strongly support the
significance of the wrpSL mechanism in HR, and existing data are
consistent with the notion that wrpSL could be a general, widely
applicable type of genetic interaction. This may refine our
understanding of relationships between gene products and will
help to improve pathway reconstruction. In particular, our
mathematical modeling provides a conceptual framework for
guiding systematic exploitation of mutations and changes in the
expression profiles of HR genes and potentially genes of other
pathways to induce SL.
Materials and Methods
Model formalism and model solution
The simplest mathematical model of Figure 3 was converted
into a set of linear ordinary differential equations using the
standard chemical kinetics formalism. The steady state model
properties were analyzed analytically and exemplified with
numerical simulations. Classification of the pathway states
according to the extreme (large or small) values of the control
Within-reversible-pathway Synthetic Lethality
PLOS Computational Biology | www.ploscompbiol.org 9 April 2013 | Volume 9 | Issue 4 | e1003016
parameters and the corresponding asymptotic solutions follow the
methodology of the asymptotology of reaction networks [54].
Numerical simulations
All numerical simulations were performed using SBTOOLBOX
package for Matlab (Section S4 in Text S1).
Supporting Information
Text S1 Text S1 contains Figure S1–S6, Section S1–S4, and Table S1.
(PDF)
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Figure 8. Examples of molecular processes with alternative pathways and potential to kinetic trap. A) Multiple post-translational protein
modifications (phosphorylation followed by ubiquitination; acetylation followed by phosphorylation; sumotargeted ubiquitination, etc.). M1 and M2
represent two types of post-translational modifications. MOD1–4 represent enzymes catalyzing the reactions. Kinetic trapping of an intermediate
modification can drastically disturb the balance between signaling pathways (e.g. #23 in Figure 2) B) Protein folding control by chaperones. Protein
folding is controlled by chaperones (#18 in Figure 2) and may generate partially unfolded proteins as toxic intermediates which are subject to
degradation [55]. Regulation of protein folding homeostasis is essential for protein pool control [56]; C) Lack of balance between production and
detoxification of ROS leads to significant increases or drop in ROS levels that can be detrimental for cell signaling [57–59] (#19 in Figure 2). D)
Coordinated sumoylation-desumoylation is important for proper signal propagation [60–62]. E) Glycan biosynthesis and protein glycosylation
depend on the availability of common carrier dolichol phosphate (P-DOL). Correct recycling of P-DOL is important for sustaining the pool and
utilization of this carrier in other glycans biosynthesis pathways. Kinetic trapping can consume the pool of P-DOL and perturb cell signaling [63,64]
(#2, 3 and 26 in Figure 2) F) Protein ubiquitylation is not only a tagging signal for degradation, but also involved in signaling. The correct tuning
between two functions of ubiquitylation depends on the type and the length of ubiquitin (UB) polymer transferred to the protein and at the
ubiquitylation site [65]. Monoubiquitylated proteins participate in signal transduction [66,67], whereas K48-polyubiquitylated proteins are redirected
to the proteasome for proteolysis. Thus, the balance between protein homeostasis and ubiquitin-dependent signaling is essential [68].
doi:10.1371/journal.pcbi.1003016.g008
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